Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

CDK4 anticorps

CDK4 Reactivité: Humain, Souris WB, IP, IHC (f) Hôte: Souris Monoclonal DCS-156 unconjugated
N° du produit ABIN967647
  • Antigène Voir toutes CDK4 Anticorps
    CDK4 (Cyclin-Dependent Kinase 4 (CDK4))
    Reactivité
    • 119
    • 75
    • 55
    • 19
    • 6
    • 5
    • 4
    • 3
    • 2
    • 1
    • 1
    • 1
    Humain, Souris
    Hôte
    • 108
    • 33
    • 2
    • 1
    Souris
    Clonalité
    • 107
    • 36
    Monoclonal
    Conjugué
    • 83
    • 11
    • 11
    • 6
    • 6
    • 5
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Cet anticorp CDK4 est non-conjugé
    Application
    • 121
    • 55
    • 37
    • 31
    • 20
    • 19
    • 16
    • 15
    • 14
    • 13
    • 7
    • 4
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), Immunoprecipitation (IP), Immunohistochemistry (Formalin-fixed Sections) (IHC (f))
    Marque
    BD Pharmingen™
     Réactivité croisée
    Souris
    Attributs du produit
    1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
    2. Please refer to us for technical protocols.
    3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
    Purification
    The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
    Immunogène
    Recombinant Human Cdk4
    Clone
    DCS-156
    Isotype
    IgG1 kappa
    Top Product
    Discover our top product CDK4 Anticorps primaire
  • Indications d'application
    Applications include western blot analysis (0.5-2.0 µg/ml) and immunoprecipitation (1.0 µg/one million cells). The antibody has also been used for immunohistochemistry of formalin-fixed, paraffin-embedded tissue sections, but this application is not routinely tested. HeLa (ATCC CCL 2), 293 (ATCC CRL 1573), or NIH/3T3 (ATCC CRL 1658) cells are suggested as positive controls.
    Commentaires

    Related Products: ABIN967389, ABIN968535

    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    0.5 mg/mL
    Buffer
    Aqueous buffered solution containing ≤0.09 % sodium azide.
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    4 °C
    Stockage commentaire
    Store undiluted at 4°C.
  • Johnson, Walker: "Cyclins and cell cycle checkpoints." dans: Annual review of pharmacology and toxicology, Vol. 39, pp. 295-312, (1999) (PubMed).

    Matsushime, Ewen, Strom, Kato, Hanks, Roussel, Sherr: "Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins." dans: Cell, Vol. 71, Issue 2, pp. 323-34, (1992) (PubMed).

  • Antigène
    CDK4 (Cyclin-Dependent Kinase 4 (CDK4))
    Autre désignation
    Cdk4 (CDK4 Produits)
    Synonymes
    anticorps zgc:153726, anticorps CMM3, anticorps PSK-J3, anticorps Crk3, anticorps 8-6, anticorps CDK4, anticorps CDK4/6, anticorps CG5072, anticorps Cdk4/6, anticorps DmCdk4, anticorps Dmel\\CG5072, anticorps Pk53C, anticorps Pk?7, anticorps cdk, anticorps cdk4, anticorps cdk4/6, anticorps dCdk4, anticorps l(2)05428, anticorps l(2)0671, anticorps l(2)k06503, anticorps l(2)s4639, anticorps l(2)sh0671, anticorps xcdk4, anticorps cyclin-dependent kinase 4, anticorps cyclin dependent kinase 4, anticorps Cyclin-dependent kinase 4, anticorps cyclin-dependent kinase 4 L homeolog, anticorps cdk4, anticorps CDK4, anticorps Cdk4, anticorps cdk4.L
    Sujet
    Cyclins, cyclin-dependent kinases (Cdks), and cyclin-dependent kinase inhibitors (CdkIs) are essential for cell-cycle control in eukarytotes. Cyclins, regulatory subunits, bind to cyclin-dependent kinases (Cdks), catalytic subunits, to form active cyclin-Cdk complexes. Cdk subunits by themselves are inactive and binding to a cyclin is required for their activity. Cyclins A, B1, D and E undergo periodic synthesis and degradation, thereby providing a mechanism to regulate Cdk activity throughout the cell cycle. Additionally, Cdk activity is further regulated by activating and inhibitory phosphorylations, and small proteins (p15, p16, p18, p19, p21 and p27), called inhibitors of Cdk activity, that bind to cyclins, Cdks, or cyclin- Cdk complexes. Cdk4 was originally called PSK-J3, and following demonstration of its association with D-type cyclins, became known as Cdk4. D-type cyclins also associate with Cdks 2 and 5, although Cdk4 appears to be the most abundant partner. The D-type cyclins (D1, D2, and D3) are expressed in response to growth factors or mitogens, and rapidly degrade when mitogens are withdrawn. D cyclins appear to promote G0 to G1 transitions and the rate of G1 progression. For example, cyclin D-Cdk4 and cyclin D-Cdk6 complexes phosphorylate the retinoblastoma protein (Rb) which removes the G1 phase block caused by underphosphorylated Rb. Cdk4 has a molecular weight of ~32 kD. Clone DCS-156 recognizes human and mouse Cdk4. A recombinant protein fragment from the C-terminal end of human Cdk4 was used as immunogen.
    Poids moléculaire
    32 kDa
    Pathways
    Cycle Cellulaire, Mitotic G1-G1/S Phases, Regulation of Cell Size
Vous êtes ici:
Support technique